Summary

Prosthetic joint infections (PJIs) demand effective therapeutic strategies like debridement, antibiotics, and irrigation with implant retention (DAIR) therapy due to their complex nature. The market is projected to reach $110.66 million in 2024 and $156.82 million in 2031, growing at a CAGR of 5.10%.These infections can be caused by various factors such as surgical site contamination, hematogenous spread of bacteria, or direct introduction during implant surgery. PJIs occur when bacteria form a biofilm on the implant surface, making them resistant to immune responses and antibiotics.

DAIR is crucial as it offers simplicity, shorter recovery time, and improved quality of life. While treatable, the success of DAIR depends on factors like the type of pathogen, antibiotic sensitivity, and early intervention, highlighting the need for innovative approaches in PJI management.

Glycopeptides, a type of drug used to treat PJIs, accounted for a significant market share. Revenue from sales of prosthetic joint infection treatment solutions contributes substantially to the global surgical site infection control market. Understanding biofilm formation can help develop targeted therapies, combination therapies, and preventive strategies. Combining antibiotics, antimicrobial agents, and biofilm-disrupting agents can increase treatment efficacy.

PJIs are a growing concern in orthopedics, especially with the increasing number of total hip and knee arthroplasty procedures. PJI leads to higher hospital readmissions, patient mortality, and substantial treatment costs. Risk factors include revision arthroscopy, prior infection, smoking, obesity, rheumatoid arthritis, cancer, immunosuppression, and diabetes mellitus. PJI diagnosis is challenging due to the virulence of pathogenic bacteria and varying patient responses. Treatment for joint infection symptoms typically involves multiple surgical procedures and prolonged medical therapy, resulting in a significant financial burden. However, following basic principles like a short symptom duration and anti-biofilm antibiotic treatment can make DAIR therapy successful in many patients.

What’s Influencing the Demand Growth for PJI Treatment?

The growing emphasis on employing DAIR procedures and multidisciplinary collaboration is driving demand for PJI treatments. This method offers simplicity, shorter recovery time, and reduced physiological damage. Research shows that successful DAIR procedures result in functional outcomes and improved quality of life comparable to uninfected cases. Variables influencing the success of DAIR include the method, antibiotic regimen, host health, and pathogen type.

Biofilms are organized microbial communities with phenotypic variations, fostering bacteria growth resistant to the host immune system and drugs. These biofilms can form on the implanted joint prosthesis, leading to persistent infections that are difficult to treat. This underscores the significance of finding innovative and effective treatment strategies to combat prosthetic joint infections caused by biofilm-forming bacteria.

Achieving success with gram-negative infections using DAIR involves early intervention and anti-biofilm antibiotic treatment. The broader scenario underscores the demand for innovative strategies in PJI treatments. PJI is a critical healthcare issue that necessitates the collaboration of a multidisciplinary team of microbiologists, infectious disease experts, rheumatologists, and orthopedics.

What are the Main Challenges Faced by Prosthetic Joint Infection Treatment Providers?

Limited success of DAIR therapy and antibiotic resistance are significant obstacles. DAIR procedures are simpler and less physiologically harmful, but their success can be limited. Patients who experience failed DAIR often require additional surgeries, leading to increased morbidity and costs. Studies suggest that a two-stage exchange after an unsuccessful DAIR may yield poor outcomes, highlighting the need for caution.

Despite DAIR's potential, outcomes can be affected by factors such as the infecting microorganism's sensitivity to antibiotics. For instance, Methicillin-resistant S. aureus (MRSA) infections often yield poor DAIR outcomes. Gram-negative microbes also pose challenges, particularly due to antibiotic resistance.

The microbial biofilm paradigm, which involves organized microbial communities with drug-resistant properties, is crucial in understanding DAIR for PJI. Biofilms generate matrices supporting bacteria growth, resisting immune response and treatment. Variables like the method, antibiotic regimen, host condition, and pathogen affect DAIR outcomes. Exchange arthroplasty has a higher chance of success than debridement alone, although methicillin resistance has little effect on how quickly wounds heal.

Country-wise Insights

United States

The United States has a significant share of the global prosthetic joint infection treatment market. Growing demand for PJI treatment in the United States can be attributed to healthcare-associated infections (HCAIs) that develop during medical care. Simple measures such as hand hygiene can prevent HCAIs, reducing morbidity, mortality, and healthcare costs. Recognizing the impact of HCAIs, efforts to promote infection control through guidelines and education are vital to addressing the demand for effective PJI treatment.

India

India also holds a significant share of the global market. Growing demand for PJI treatment in India is intertwined with the remarkable growth of its healthcare sector. Driven by factors like medical tourism, the Indian healthcare industry has witnessed significant growth. India's medical tourism sector offers competitive pricing, skilled medical professionals, high-quality care, and a diverse array of treatments. Government initiatives further amplify India's appeal as a medical travel destination.

China

Demand for PJI treatment in China is growing due to the expanding patient pool requiring artificial joint replacement procedures. Total hip arthroplasty (THA) and total knee arthroplasty (TKA) cases have significantly increased, with more preference for domestic implants. PJIs pose a significant therapeutic challenge as being a complication post total joint arthroplasty (TJA) and lead to an increased socioeconomic burden on the Chinese healthcare system. This is predicted to drive the demand for PJI treatment solutions in China.

Category-wise Insights

Pharmaceutical Agents

Glycopeptides are the most widely used pharmaceutical agents for PJI treatment. These antibiotics, including vancomycin and teicoplanin, are essential in managing severe bacterial infections, especially those caused by methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci. Due to their potent bactericidal effects and coverage against a range of pathogens, glycopeptides are often used as first-line therapies or in combination with other antibiotics for PJI. Their ability to target resistant strains and provide effective treatment makes them a crucial choice in addressing the challenging infections associated with prosthetic joint replacements, ensuring improved patient outcomes and reduced risk of complications.

Types of Infections

Post-operative infections are the most prevalent and require extensive treatment. These infections frequently need specialist care, such as antibiotics and, in severe situations, surgery to remove the infected implant. The complexity and severity of post-operative infections fuel the demand for innovative and effective treatment solutions, leading to high revenue generation for market players.

Pathogens

Staphylococcus aureus is the most common pathogen in PJIs. Early infections, occurring during the first four weeks following the initial surgery, are typically caused by Staphylococcus aureus due to its aggressive nature and ubiquity in generating infections. This pathogen is known to develop biofilms, making infections difficult to treat and recurring. Effective treatment options for Staphylococcus aureus and associated biofilm are critical, fueling demand for specialist therapies and generating significant income.

Routes of Administration

The intravenous administration route is widely preferred for PJI treatment due to its direct and rapid delivery of antibiotics into the bloodstream. Intravenous antibiotics ensure effective and targeted treatment, reaching the infection site directly. This route is preferred for severe cases of prosthetic joint infections, ensuring higher concentrations of antibiotics are delivered quickly to combat the infection. Intravenous administration also allows for close monitoring and adjustment of the treatment regimen, contributing to better patient outcomes.

Competition Analysis

The prosthetic joint infection treatment industry is highly fragmented, with several competitors offering products and services locally. These businesses are using strategies such as business expansion and innovation to meet patients’ demands and grow their customer base.

Recent developments include the collaboration between the University of Buffalo researchers and Garwood Medical Devices to evaluate BioPrax, a medical device that uses UB-licensed technology to prevent, control, and eliminate bacterial biofilm infections in orthopedic implants. Additionally, Peptilogics received FDA QIDP designation for its PLG0206 treatment for PJIs, potentially reducing inpatient costs.

Key Companies Covered

Several key companies dominate the market, including Pfizer Inc., Novartis AG, Mylan N.V., Teva Pharmaceuticals, Merck & Co., Eli Lilly & Company, AstraZeneca PLC, Lupin Limited, Dr. Reddys Laboratories, Aurobindo Pharma Ltd., GSK PLC, Sun Pharmaceutical Industries Ltd., and Cipla Ltd.

Key Segments of Prosthetic Joint Infection Treatment Industry

By Drug:

•Aminoglycosides

•Glycopeptides

•Rifamycin

•Lincosamide

•Penicillin

•Other Antibiotics

By Infection:

•Pre-operative Infection

•Post-operative Infection

By Route of Administration:

•Oral

•Intravenous

By Pathogen:

•Staphylococcus Aureus

•Coagulase-negative Staphylococcus

•Candida Species

•Enterococcus Species

•Other Pathogens

By Distribution Channel:

•Hospital Pharmacies

•Retail Pharmacies

•Drug Stores

•Online Sales

By Region:

•North America

•Latin America

•Europe

•South Asia

•East Asia

•Oceania

•Middle East and Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Prosthetic Joint Infections Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2024
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Prosthetic Joint Infections Treatment Market Outlook, 2019-2031
3.1. Global Prosthetic Joint Infections Treatment Market Outlook, by Drug, Value (US$ Mn), 2019-2031
3.1.1. Key Highlights
3.1.1.1. Aminoglycosides
3.1.1.2. Glycopeptides
3.1.1.3. Rifamycin
3.1.1.4. Lincosamide
3.1.1.5. Penicillin
3.1.1.6. Other Antibiotics
3.2. Global Prosthetic Joint Infections Treatment Market Outlook, by Infection, Value (US$ Mn), 2019-2031
3.2.1. Key Highlights
3.2.1.1. Pre-operative Infection
3.2.1.2. Post-operative Infection
3.3. Global Prosthetic Joint Infections Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2019-2031
3.3.1. Key Highlights
3.3.1.1. Oral
3.3.1.2. Intravenous
3.4. Global Prosthetic Joint Infections Treatment Market Outlook, by Pathogen, Value (US$ Mn), 2019-2031
3.4.1. Key Highlights
3.4.1.1. Staphylococcus Aureus
3.4.1.2. Coagulase-negative Staphylococcus
3.4.1.3. Candida Species
3.4.1.4. Enterococcus Species
3.4.1.5. Others
3.5. Global Prosthetic Joint Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2019-2031
3.5.1. Key Highlights
3.5.1.1. Hospital Pharmacies
3.5.1.2. Retail Pharmacies
3.5.1.3. Drug Stores
3.5.1.4. Online Sales
3.6. Global Prosthetic Joint Infections Treatment Market Outlook, by Region, Value (US$ Mn), 2019-2031
3.6.1. Key Highlights
3.6.1.1. North America
3.6.1.2. Europe
3.6.1.3. Asia Pacific
3.6.1.4. Latin America
3.6.1.5. Middle East & Africa
4. North America Prosthetic Joint Infections Treatment Market Outlook, 2019-2031
4.1. North America Prosthetic Joint Infections Treatment Market Outlook, by Drug, Value (US$ Mn), 2019-2031
4.1.1. Key Highlights
4.1.1.1. Aminoglycosides
4.1.1.2. Glycopeptides
4.1.1.3. Rifamycin
4.1.1.4. Lincosamide
4.1.1.5. Penicillin
4.1.1.6. Other Antibiotics
4.2. North America Prosthetic Joint Infections Treatment Market Outlook, by Infection, Value (US$ Mn), 2019-2031
4.2.1. Key Highlights
4.2.1.1. Pre-operative Infection
4.2.1.2. Post-operative Infection
4.3. North America Prosthetic Joint Infections Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2019-2031
4.3.1. Key Highlights
4.3.1.1. Oral
4.3.1.2. Intravenous
4.4. North America Prosthetic Joint Infections Treatment Market Outlook, by Pathogen, Value (US$ Mn), 2019-2031
4.4.1. Key Highlights
4.4.1.1. Staphylococcus Aureus
4.4.1.2. Coagulase-negative Staphylococcus
4.4.1.3. Candida Species
4.4.1.4. Enterococcus Species
4.4.1.5. Others
4.5. North America Prosthetic Joint Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2019-2031
4.5.1. Key Highlights
4.5.1.1. Hospital Pharmacies
4.5.1.2. Retail Pharmacies
4.5.1.3. Drug Stores
4.5.1.4. Online Sales
4.6. North America Prosthetic Joint Infections Treatment Market Outlook, by Country, Value (US$ Mn), 2019-2031
4.6.1. Key Highlights
4.6.1.1. U.S. Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
4.6.1.2. U.S. Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
4.6.1.3. U.S. Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
4.6.1.4. U.S. Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
4.6.1.5. U.S. Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
4.6.1.6. Canada Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
4.6.1.7. Canada Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
4.6.1.8. Canada Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
4.6.1.9. Canada Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
4.6.1.10. Canada Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
4.6.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Prosthetic Joint Infections Treatment Market Outlook, 2019-2031
5.1. Europe Prosthetic Joint Infections Treatment Market Outlook, by Drug, Value (US$ Mn), 2019-2031
5.1.1. Key Highlights
5.1.1.1. Aminoglycosides
5.1.1.2. Glycopeptides
5.1.1.3. Rifamycin
5.1.1.4. Lincosamide
5.1.1.5. Penicillin
5.1.1.6. Other Antibiotics
5.2. Europe Prosthetic Joint Infections Treatment Market Outlook, by Infection, Value (US$ Mn), 2019-2031
5.2.1. Key Highlights
5.2.1.1. Pre-operative Infection
5.2.1.2. Post-operative Infection
5.3. Europe Prosthetic Joint Infections Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2019-2031
5.3.1. Key Highlights
5.3.1.1. Oral
5.3.1.2. Intravenous
5.4. Europe Prosthetic Joint Infections Treatment Market Outlook, by Pathogen, Value (US$ Mn), 2019-2031
5.4.1. Key Highlights
5.4.1.1. Staphylococcus Aureus
5.4.1.2. Coagulase-negative Staphylococcus
5.4.1.3. Candida Species
5.4.1.4. Enterococcus Species
5.4.1.5. Others
5.5. Europe Prosthetic Joint Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2019-2031
5.5.1. Key Highlights
5.5.1.1. Hospital Pharmacies
5.5.1.2. Retail Pharmacies
5.5.1.3. Drug Stores
5.5.1.4. Online Sales
5.6. Europe Prosthetic Joint Infections Treatment Market Outlook, by Country, Value (US$ Mn), 2019-2031
5.6.1. Key Highlights
5.6.1.1. Germany Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
5.6.1.2. Germany Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
5.6.1.3. Germany Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
5.6.1.4. Germany Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
5.6.1.5. Germany Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
5.6.1.6. U.K. Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
5.6.1.7. U.K. Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
5.6.1.8. U.K. Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
5.6.1.9. U.K. Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
5.6.1.10. U.K. Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
5.6.1.11. France Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
5.6.1.12. France Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
5.6.1.13. France Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
5.6.1.14. France Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
5.6.1.15. France Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
5.6.1.16. Italy Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
5.6.1.17. Italy Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
5.6.1.18. Italy Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
5.6.1.19. Italy Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
5.6.1.20. Italy Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
5.6.1.21. Turkey Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
5.6.1.22. Turkey Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
5.6.1.23. Turkey Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
5.6.1.24. Turkey Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
5.6.1.25. Turkey Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
5.6.1.26. Russia Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
5.6.1.27. Russia Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
5.6.1.28. Russia Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
5.6.1.29. Russia Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
5.6.1.30. Russia Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
5.6.1.31. Rest of Europe Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
5.6.1.32. Rest of Europe Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
5.6.1.33. Rest of Europe Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
5.6.1.34. Rest of Europe Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
5.6.1.35. Rest of Europe Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
5.6.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, 2019-2031
6.1. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, by Drug, Value (US$ Mn), 2019-2031
6.1.1. Key Highlights
6.1.1.1. Aminoglycosides
6.1.1.2. Glycopeptides
6.1.1.3. Rifamycin
6.1.1.4. Lincosamide
6.1.1.5. Penicillin
6.1.1.6. Other Antibiotics
6.2. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, by Infection, Value (US$ Mn), 2019-2031
6.2.1. Key Highlights
6.2.1.1. Pre-operative Infection
6.2.1.2. Post-operative Infection
6.3. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2019-2031
6.3.1. Key Highlights
6.3.1.1. Oral
6.3.1.2. Intravenous
6.4. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, by Pathogen, Value (US$ Mn), 2019-2031
6.4.1. Key Highlights
6.4.1.1. Staphylococcus Aureus
6.4.1.2. Coagulase-negative Staphylococcus
6.4.1.3. Candida Species
6.4.1.4. Enterococcus Species
6.4.1.5. Others
6.5. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2019-2031
6.5.1. Key Highlights
6.5.1.1. Hospital Pharmacies
6.5.1.2. Retail Pharmacies
6.5.1.3. Drug Stores
6.5.1.4. Online Sales
6.6. Asia Pacific Prosthetic Joint Infections Treatment Market Outlook, by Country, Value (US$ Mn), 2019-2031
6.6.1. Key Highlights
6.6.1.1. China Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
6.6.1.2. China Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
6.6.1.3. China Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
6.6.1.4. China Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
6.6.1.5. China Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
6.6.1.6. Japan Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
6.6.1.7. Japan Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
6.6.1.8. Japan Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
6.6.1.9. Japan Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
6.6.1.10. Japan Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
6.6.1.11. South Korea Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
6.6.1.12. South Korea Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
6.6.1.13. South Korea Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
6.6.1.14. South Korea Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
6.6.1.15. South Korea Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
6.6.1.16. India Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
6.6.1.17. India Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
6.6.1.18. India Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
6.6.1.19. India Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
6.6.1.20. India Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
6.6.1.21. Southeast Asia Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
6.6.1.22. Southeast Asia Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
6.6.1.23. Southeast Asia Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
6.6.1.24. Southeast Asia Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
6.6.1.25. Southeast Asia Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
6.6.1.26. Rest of Asia Pacific Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
6.6.1.27. Rest of Asia Pacific Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
6.6.1.28. Rest of Asia Pacific Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
6.6.1.29. Rest of Asia Pacific Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
6.6.1.30. Rest of Asia Pacific Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
6.6.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Prosthetic Joint Infections Treatment Market Outlook, 2019-2031
7.1. Latin America Prosthetic Joint Infections Treatment Market Outlook, by Drug, Value (US$ Mn), 2019-2031
7.1.1. Key Highlights
7.1.1.1. Aminoglycosides
7.1.1.2. Glycopeptides
7.1.1.3. Rifamycin
7.1.1.4. Lincosamide
7.1.1.5. Penicillin
7.1.1.6. Other Antibiotics
7.2. Latin America Prosthetic Joint Infections Treatment Market Outlook, by Infection, Value (US$ Mn), 2019-2031
7.2.1. Key Highlights
7.2.1.1. Pre-operative Infection
7.2.1.2. Post-operative Infection
7.3. Latin America Prosthetic Joint Infections Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2019-2031
7.3.1. Key Highlights
7.3.1.1. Oral
7.3.1.2. Intravenous
7.4. Latin America Prosthetic Joint Infections Treatment Market Outlook, by Pathogen, Value (US$ Mn), 2019-2031
7.4.1. Key Highlights
7.4.1.1. Staphylococcus Aureus
7.4.1.2. Coagulase-negative Staphylococcus
7.4.1.3. Candida Species
7.4.1.4. Enterococcus Species
7.4.1.5. Others
7.5. Latin America Prosthetic Joint Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2019-2031
7.5.1. Key Highlights
7.5.1.1. Hospital Pharmacies
7.5.1.2. Retail Pharmacies
7.5.1.3. Drug Stores
7.5.1.4. Online Sales
7.6. Latin America Prosthetic Joint Infections Treatment Market Outlook, by Country, Value (US$ Mn), 2019-2031
7.6.1. Key Highlights
7.6.1.1. Brazil Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
7.6.1.2. Brazil Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
7.6.1.3. Brazil Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
7.6.1.4. Brazil Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
7.6.1.5. Brazil Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
7.6.1.6. Mexico Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
7.6.1.7. Mexico Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
7.6.1.8. Mexico Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
7.6.1.9. Mexico Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
7.6.1.10. Mexico Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
7.6.1.11. Argentina Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
7.6.1.12. Argentina Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
7.6.1.13. Argentina Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
7.6.1.14. Argentina Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
7.6.1.15. Argentina Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
7.6.1.16. Rest of Latin America Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
7.6.1.17. Rest of Latin America Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
7.6.1.18. Rest of Latin America Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
7.6.1.19. Rest of Latin America Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
7.6.1.20. Rest of Latin America Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
7.6.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, 2019-2031
8.1. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, by Drug, Value (US$ Mn), 2019-2031
8.1.1. Key Highlights
8.1.1.1. Aminoglycosides
8.1.1.2. Glycopeptides
8.1.1.3. Rifamycin
8.1.1.4. Lincosamide
8.1.1.5. Penicillin
8.1.1.6. Other Antibiotics
8.2. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, by Infection, Value (US$ Mn), 2019-2031
8.2.1. Key Highlights
8.2.1.1. Pre-operative Infection
8.2.1.2. Post-operative Infection
8.3. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2019-2031
8.3.1. Key Highlights
8.3.1.1. Oral
8.3.1.2. Intravenous
8.4. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, by Pathogen, Value (US$ Mn), 2019-2031
8.4.1. Key Highlights
8.4.1.1. Staphylococcus Aureus
8.4.1.2. Coagulase-negative Staphylococcus
8.4.1.3. Candida Species
8.4.1.4. Enterococcus Species
8.4.1.5. Others
8.5. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2019-2031
8.5.1. Key Highlights
8.5.1.1. Hospital Pharmacies
8.5.1.2. Retail Pharmacies
8.5.1.3. Drug Stores
8.5.1.4. Online Sales
8.6. Middle East & Africa Prosthetic Joint Infections Treatment Market Outlook, by Country, Value (US$ Mn), 2019-2031
8.6.1. Key Highlights
8.6.1.1. GCC Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
8.6.1.2. GCC Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
8.6.1.3. GCC Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
8.6.1.4. GCC Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
8.6.1.5. GCC Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
8.6.1.6. South Africa Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
8.6.1.7. South Africa Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
8.6.1.8. South Africa Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
8.6.1.9. South Africa Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
8.6.1.10. South Africa Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
8.6.1.11. Egypt Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
8.6.1.12. Egypt Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
8.6.1.13. Egypt Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
8.6.1.14. Egypt Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
8.6.1.15. Egypt Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
8.6.1.16. Nigeria Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
8.6.1.17. Nigeria Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
8.6.1.18. Nigeria Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
8.6.1.19. Nigeria Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
8.6.1.20. Nigeria Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
8.6.1.21. Rest of Middle East & Africa Prosthetic Joint Infections Treatment Market by Drug, Value (US$ Mn), 2019-2031
8.6.1.22. Rest of Middle East & Africa Prosthetic Joint Infections Treatment Market by Infection, Value (US$ Mn), 2019-2031
8.6.1.23. Rest of Middle East & Africa Prosthetic Joint Infections Treatment Market by Route of Administration, Value (US$ Mn), 2019-2031
8.6.1.24. Rest of Middle East & Africa Prosthetic Joint Infections Treatment Market by Pathogen, Value (US$ Mn), 2019-2031
8.6.1.25. Rest of Middle East & Africa Prosthetic Joint Infections Treatment Market by Distribution Channel, Value (US$ Mn), 2019-2031
8.6.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Product vs Indication Heatmap
9.2. Company Market Share Analysis, 2024
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Pfizer Inc.
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Novartis AG
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Mylan N.V.
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Teva Pharmaceuticals
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Merck & Co.
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Eli Lilly & Company
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. AstraZeneca PLC
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Lupin Limited
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Dr. Reddys Laboratories
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Aurobindo Pharma Ltd.
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
9.4.11. GSK PLC
9.4.11.1. Company Overview
9.4.11.2. Product Portfolio
9.4.11.3. Financial Overview
9.4.11.4. Business Strategies and Development
9.4.12. Sun Pharmaceutical Industries Ltd.
9.4.12.1. Company Overview
9.4.12.2. Product Portfolio
9.4.12.3. Financial Overview
9.4.12.4. Business Strategies and Development
9.4.13. Cipla Ltd.
9.4.13.1. Company Overview
9.4.13.2. Product Portfolio
9.4.13.3. Financial Overview
9.4.13.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations